Want to join the conversation?
$BMY 2Q15 Call: Delivered 7% overall sales growth YoverY. For Opdivo, had three early study stops, significant data presented at ASCO, three filings, three approvals, and commercial launches in both US & Europe. In Europe, Opdivo was approved for squamous lung cancer in this week. Expects to complete filing of 57 data in US & Europe in this week.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.